Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone vs placebo in Becker muscular dystrophy (Phase II pilot)
2022-000844-31Phase 2Completed
- Sponsor
- ReveraGen BioPharma
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Becker muscular dystrophy (BMD) comparing Vamorolone arm with Placebo arm (2 arms). Primary endpoint: Safety and tolerability of vamorolone. Started Nov 2022; status: completed.
02
Drugs
vamorolone
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on 2022-000844-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000844-31.